Table of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute USD Opportunity Assessment & Y-o-Y Analysis, 2022-2035
2.3 Market Size & Forecast, By Segmentation, 2022-2035
2.3.1 Market Size By Model Type
2.3.2 Market Size By Modality
2.3.3 Market Size By Indication
2.3.4 Market Size By GLP Type
2.4 Market Share & Bps Analysis By Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Service Type & Study Model Metrics
4.1.1 Toxicology studies – acute, sub-chronic, and chronic toxicity testing
4.1.2 Pharmacokinetics (PK) and pharmacodynamics (PD) studies
4.1.3 Efficacy and disease model studies (oncology, CNS, metabolic disorders)
4.1.4 Safety pharmacology and IND-enabling studies
4.1.5 Bioanalysis and biomarker testing services
4.1.6 GLP-compliant vs non-GLP research services
4.1.7 Custom vs standardized preclinical study models
4.2 Study Execution & Operational Efficiency Metrics
4.2.1 Study initiation timelines and setup efficiency
4.2.2 Animal model preparation and readiness time
4.2.3 Study duration by therapeutic area
4.2.4 Protocol adherence and deviation rates
4.2.5 Data turnaround time and reporting speed
4.2.6 Resource utilization (lab capacity, personnel)
4.2.7 On-time study completion rates
4.3 Animal Model & Species Utilization Metrics
4.3.1 Rodent vs non-rodent model usage distribution
4.3.2 Transgenic and humanized animal model adoption
4.3.3 Disease-specific model accuracy and relevance
4.3.4 Animal welfare compliance and ethical standards
4.3.5 Reproducibility of in vivo study outcomes
4.3.6 Model availability and scalability
4.3.7 Reduction, refinement, and replacement (3Rs) implementation
5. In Vivo CRO Market Segmental Analysis & Forecast, By Model Type, 2022 – 2035, Value (USD Billion)
5.1 Introduction
5.2 Rodent based
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022 – 2035
5.2.3 Mice Models
5.2.4 Rat Models
5.2.5 Others
5.3 Non-rodent base
6. In Vivo CRO Market Segmental Analysis & Forecast, By Modality, 2022 – 2035, Value (USD Billion)
6.1 Introduction
6.2 Small Molecules
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022 – 2035
6.3 Large Molecules
6.3.1 Cell & Gene Therapy
6.3.1.1 CAR T-cell therapies
6.3.1.2 CAR-NK cell therapy
6.3.1.3 TCR-T cell therapy
6.3.1.4 Other (Includes- TCR-NK, CARM, and TAC-T)
6.3.2 RNA Therapy
6.3.3 Others
7. In Vivo CRO Market Segmental Analysis & Forecast, By Indication, 2022 – 2035, Value (USD Billion)
7.1 Introduction
7.2 Oncology
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022 – 2035
7.2.3 Blood cancer
7.2.4 Solid tumor
7.2.4.1 Syngeneic model
7.2.4.2 Patient derived xenograft
7.2.4.3 Xenograft
7.2.5 Others
7.3 CNS Conditions
7.3.1 Epilepsy
7.3.2 Parkinson's disease
7.3.3 Muscular Dystrophy
7.3.4 Huntington's disease
7.3.5 Strok
7.3.6 Alzheimer’s Disease
7.3.7 Muscle regeneration
7.3.8 Traumatic brain injury
7.3.9 Amyotrophic lateral sclerosis (ALS)
7.3.10 Spinal Muscular Atrophy
7.3.11 Other Neurodevelopment Disorders
7.4 Diabetes
7.5 Obesity
7.6 Pain management
7.6.1 Chronic pain
7.6.2 Acute pain
7.7 Autoimmune/inflammation conditions
7.7.1 Rheumatoid Arthritis
7.7.2 Irritable Bowel Syndrome
7.7.3 Multiple Sclerosis
7.2.4 Osteoarthritis
7.2.5 Others
7.8 Others
8. In Vivo CRO Market Segmental Analysis & Forecast, By GLP Type, 2022 – 2035, Value (USD Billion)
8.1 Introduction
8.2 GLP Toxicology
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022 – 2035
8.3 Non GLP
9. In Vivo CRO Market Segmental Analysis & Forecast By Region, 2022 – 2035, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 In Vivo CRO Market Size & Forecast, By Model Type, 2022 – 2035
9.2.3 In Vivo CRO Market Size & Forecast, By Modality, 2022 – 2035
9.2.4 In Vivo CRO Market Size & Forecast, By Indication, 2022 – 2035
9.2.5 In Vivo CRO Market Size & Forecast, By GLP Type, 2022 – 2035
9.2.6 In Vivo CRO Market Size & Forecast, By Country, 2022 – 2035
9.2.6.1 USA
9.2.6.2 Canada
9.3 Europe
9.3.1 Key Trends
9.3.2 In Vivo CRO Market Size & Forecast, By Model Type, 2022 – 2035
9.3.3 In Vivo CRO Market Size & Forecast, By Modality, 2022 – 2035
9.3.4 In Vivo CRO Market Size & Forecast, By Indication, 2022 – 2035
9.3.5 In Vivo CRO Market Size & Forecast, By GLP Type, 2022 – 2035
9.3.6 In Vivo CRO Market Size & Forecast, By Country, 2022 – 2035
9.3.6.1 Germany
9.3.6.2 UK
9.3.6.3 France
9.3.6.4 Italy
9.3.6.5 Spain
9.3.6.6 Russia
9.3.6.7 Poland
9.3.6.8 Rest of Europe
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 In Vivo CRO Market Size & Forecast, By Model Type, 2022 – 2035
9.4.3 In Vivo CRO Market Size & Forecast, By Modality, 2022 – 2035
9.4.4 In Vivo CRO Market Size & Forecast, By Indication, 2022 – 2035
9.4.5 In Vivo CRO Market Size & Forecast, By GLP Type, 2022 – 2035
9.4.6 In Vivo CRO Market Size & Forecast, By Country, 2022 – 2035
9.4.6.1 China
9.4.6.2 India
9.4.6.3 Japan
9.4.6.4 South Korea
9.4.6.5 Australia
9.4.6.6 ASEAN Countries
9.4.6.7 Rest of Asia-Pacific
9.5 Latin America
9.5.1 Key Trends
9.5.2 In Vivo CRO Market Size & Forecast, By Model Type, 2022 – 2035
9.5.3 In Vivo CRO Market Size & Forecast, By Modality, 2022 – 2035
9.5.4 In Vivo CRO Market Size & Forecast, By Indication, 2022 – 2035
9.5.5 In Vivo CRO Market Size & Forecast, By GLP Type, 2022 – 2035
9.5.6 In Vivo CRO Market Size & Forecast, By Country, 2022 – 2035
9.5.6.1 Brazil
9.5.6.2 Argentina
9.5.6.3 Mexico
9.5.6.4 Colombia
9.5.6.5 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 In Vivo CRO Market Size & Forecast, By Model Type, 2022 – 2035
9.6.3 In Vivo CRO Market Size & Forecast, By Modality, 2022 – 2035
9.6.4 In Vivo CRO Market Size & Forecast, By Indication, 2022 – 2035
9.6.5 In Vivo CRO Market Size & Forecast, By GLP Type, 2022 – 2035
9.6.6 In Vivo CRO Market Size & Forecast, By Country, 2022 – 2035
9.6.6.1 UAE
9.6.6.2 Saudi Arabia
9.6.6.3 Qatar
9.6.6.4 Egypt
9.6.6.5 South Africa
9.6.6.6 Rest of Middle East & Africa
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2025
10.2.2 Year-Wise Strategies & Development, 2022 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2025
10.3 Market Share Analysis, 2025
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6.1 Charles River Laboratories International Inc.
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Labcorp Drug Development (Covance)
10.6.3 ICON plc
10.6.4 WuXi AppTec Co. Ltd.
10.6.5 Envigo (Inotiv)
10.6.6 Eurofins Scientific SE
10.6.7 Medpace Holdings Inc.
10.6.8 PRA Health Sciences (ICON)
10.6.9 Syneos Health Inc.
10.6.10 PPD (Pharmaceutical Product Development)
10.6.11 Crown Bioscience (JSR)
10.6.12 Taconic Biosciences Inc.
10.6.13 The Jackson Laboratory
10.6.14 Champions Oncology Inc.
10.6.15 GemPharmatech Co. Ltd.
10.6.16 Biocytogen Pharmaceuticals Ltd.
10.6.17 Evotec SE
10.6.18 Calvert Laboratories
10.6.19 EPL Bio Analytical Services
10.6.20 BioAnalytical Systems Inc. (BAS)
11. Analyst Recommendation
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions on Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Frequently Asked Questions
Asia Pacific is expected to register the fastest CAGR, with India projected to have the highest CAGR within the region.
North America dominated the In Vivo CRO Market with approximately 49% share in 2025.
Rodent-based models dominated with approximately 80% share in 2025.
The In Vivo CRO Market was valued at USD 5.48 billion in 2025.
The In Vivo CRO Market is expected to grow at a CAGR of 8.0% from 2026 to 2035.
Get in Touch
